Semaglutide vs. tirzepatide: how they differ

Quick answer

Semaglutide mimics the hormone GLP-1. Tirzepatide mimics both GLP-1 and GIP. Both target areas of the brain involved in appetite and food intake. That difference does not, by itself, tell you which medicine fits your health needs. The evidence cited here does not include a direct comparison that establishes a winner. Results vary. A clinician should weigh your medical history, other medicines, possible side effects, and costs before recommending either option.

Different hormone targets, not a simple ranking

GLP-1 stands for glucagon-like peptide-1. GIP stands for glucose-dependent insulinotropic polypeptide. The names are long, but the basic distinction is clear: semaglutide mimics one of these hormones, while tirzepatide mimics both. NIDDK describes both medicines as targeting brain areas that regulate appetite and food intake. This explains how their actions differ. It does not show that targeting more hormones is always better or safer for every person.

A useful comparison separates how a medicine works from what happens during treatment. Hormone targets describe its action. Weight change, side effects, and the ability to continue treatment describe outcomes. Results vary, and these outcomes need their own evidence. If you hear that one option is automatically stronger because it has another target, ask what research supports that claim and whether it studied the exact product being discussed.

Product names and treatment purpose matter

In the supplied NIDDK guide, Wegovy is the semaglutide product listed for long-term weight management. Zepbound is the tirzepatide product listed for that purpose. The guide describes both as injections. It also names semaglutide products used for type 2 diabetes, including Ozempic and Rybelsus, and the tirzepatide diabetes product Mounjaro. Knowing the ingredient alone does not tell you the full treatment purpose or which product a clinician is considering.

Ask the clinician to write down the exact product name and explain why it is being considered. Also ask whether the proposed use matches its FDA-approved purpose. NIDDK calls use outside an approved purpose off-label use. That term deserves a clear explanation, not an assumption that all products with a shared ingredient can be used in the same way. This article does not provide instructions for switching products or using one in place of another.

What the evidence cited here can and cannot compare

NIDDK explains that prescription weight-management medicines can help some people lose weight when combined with eating, activity, and behavior changes. Results vary by medicine and person. Its broad findings cover several treatments, not just semaglutide and tirzepatide. Those findings should not become a promised result for either medicine. They also do not provide a direct answer about which option would lead to more weight loss for you personally.

When reviewing a comparison, ask whether researchers studied the medicines together in the same trial or reported them in separate studies. Ask which products, people, and outcomes were included. The supplied excerpts do not give enough direct comparison data to rank these medicines by weight loss or side effects. A careful discussion can acknowledge that gap while still comparing established differences in their hormone targets, product names, and shared safety warnings.

Who may be considered for medication

NIDDK says clinicians may consider weight-management medication for adults with a BMI of 30 or greater. They may also consider it for adults with a BMI of 27 or greater who have weight-related health problems. Examples include high blood pressure and type 2 diabetes. BMI compares weight with height. It helps guide the discussion, but it is not the whole decision. Not everyone with a high BMI needs medication.

Your current health conditions, family history, and other treatments can change which options deserve discussion. Cost matters, too. Rather than asking only whether you qualify for semaglutide or tirzepatide, ask what health concern the treatment would address. A clinician may discuss a lifestyle program, medication, or another approach. Choosing not to prescribe either medicine can be a reasonable result of a careful review, not a judgment about your effort or worth.

Shared warnings deserve close attention

The supplied NIDDK guide lists the same important restriction for semaglutide and tirzepatide: do not take them with a personal or family history of medullary thyroid cancer, called MTC, or multiple endocrine neoplasia syndrome type 2, called MEN 2. Bring any known family diagnoses to the visit. If you only know that a relative had thyroid cancer, say that the type is unclear rather than guessing or leaving it out.

NIDDK also advises against weight-loss medicines during pregnancy or when planning pregnancy. It says these medicines are not recommended while breastfeeding. Discuss these circumstances before treatment. Share allergies and every prescription, nonprescription medicine, vitamin, and supplement you use. Possible side effects and interactions need a product-specific review. Ask which symptoms need a prompt call and which need emergency care. For emergency symptoms, call 911; never wait for an online reply.

Compounded medicine requires a separate discussion

Compounded medicine is not FDA-approved. Research on an FDA-approved manufactured product must not be presented as evidence for a compounded version. A familiar ingredient name does not remove that distinction. If a compounded medicine enters the discussion, ask why it is being considered, which pharmacy would prepare it, and what information supports the proposed choice. Results vary, and claims about a manufactured product should not become promises about a compounded preparation.

Keep the comparison specific: are you discussing two FDA-approved manufactured products, a manufactured product and a compounded preparation, or something else? Those are different questions. Ask for the exact medicine, its source, and clear written directions if prescribed. NIDDK advises buying medication from a pharmacy or online distributor approved by your clinician. Do not combine weight-loss medicines with other weight-loss products unless a health care professional has prescribed that combination.

Practical differences to discuss before deciding

A medicine must fit more than a comparison chart. Ask about the total cost of visits, medication, and any recommended tests. Insurance coverage for weight-management medicines varies, so check the exact product with your plan. Ask how follow-up would work and whom to contact about problems. If access or cost becomes a barrier, discuss the next step with the clinician rather than borrowing medicine, changing products, or creating your own dosing plan.

Make the visit a shared decision

Bring a short weight history, past treatment experiences, current medicine list, family health history, and your main questions. Ask how the clinician would judge benefit, review side effects, and decide whether the plan still fits. Results vary, so arrange a review rather than expecting a fixed outcome. Semaglutide and tirzepatide differ in hormone targets, but the better question is which approach, if any, makes sense for your health and circumstances.